SGLT2 inhibitors and Sleep apnea; How Helpful are the Medications: A Meta-analysisSleep apneaSGLT2 inhibitorsSleep disordered breathingDiabetesBackground Sleep disordered breathing (SDB) has a close association with diabetes, especially in obese patients. The use of sodium-glucose co-transporter-2 (...
Among 223 subjects, 114 patients had been given RAS inhibitors as background medications when SGLT2 inhibitors were started (Table1). Baseline eGFR did not differ between the RAS inhibitor-treated and untreated groups (Fig.2a). In subjects without RAS inhibitor treatment, the administration of SGL...
slow renal disease progression but eGFR either stabilises after the initial dip or slowly declines over a similar period (negative eGFR slope) [49,50]. In addition, cardiorenal syndrome severely limits the available options of HF medications (ACE-inhibitors/ARBs, MRAs and ARNIs), all of which ...
Patients with HFpEF and NYHA class II-III with frequent symptoms or hospitalizations for heart failure derive the most benefit from SGLT2 inhibitors with an overall goal of a reduction in heart failure hospitalizations. Conclusions: The treatment of HFpEF has made progress, but there is still work...
Second, SGLT2 inhibitors may increase myocardial energy production; alleviate systemic microvascular dysfunction, which is prevalent in both the myocardium and skeletal muscle in HFpEF; improve systemic endothelial function; reduce systemic inflammation and oxidative stress; and improve insulin sensitivity and...
SGLT2 inhibitors mitigate cellular senescence through ANGPTL4 modulation.A–DP53 and P21 proteins in cell lysates were detected by Western blotting.EandFβ-gal staining of treated AC16 cells; scale bar, 20 mm.GandHImmunofluorescent staining of γ-H2AX (green) in treated AC16 cells; scale bar...
3. SGLT2 inhibitors (SGLT2-I) 4. Role of SGLT2-I in cardio-protection 5. Medicinal chemistry approaches toward SGLT2-I 6. In silico studies toward the design of SGLT2-I 7. Summary and conclusion Declaration of competing interest Acknowledgment List of abbreviations ReferencesShow full outline...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are antidiabetic medications which act by inhibiting the reabsorption of sodium and glucose in the proximal tubules of the kidney [13]. Commonly used SGLT2i include canagliflozin, dapagliflozin, and empagliflozin [13]. The cardioprotective effects of...
(SGLT-2) inhibitors present potent nephroprotective properties. In clinical trials in patients with type 2 diabetes mellitus, these agents were shown to reduce albuminuria and proteinuria by 30–50% and the incidence of composite hard renal outcomes by 40–50%. Furthermore, their mechanism of ...
Most participants in these trials were treated with appropriate cardiovascular medications, including beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, antiplatelet medications, and statins. Similar to prior trials, the mean age was between 50 and 60 years, so it is challenging to ...